D.E. Shaw & Co’s Juno Therapeutics, Inc. JUNO Stock Holding History

D.E. Shaw & Co’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-20,000	Closed	-$914K	–	3954
2017 Q4	$914K	Hold	20,000	–	–	﹤0.01%	2631
2017 Q3	$897K	Hold	20,000	–	–	﹤0.01%	2556
2017 Q2	$598K	Hold	20,000	–	–	﹤0.01%	2724
2017 Q1	$444K	Hold	20,000	–	–	﹤0.01%	2785
2016 Q4	$377K	Buy	+20,000	New	+$489K	﹤0.01%	3008
2016 Q3	–	Sell	-20,000	Closed	-$769K	–	3674
2016 Q2	$769K	Sell	20,000 -30,000	-60%	-$1.25M	﹤0.01%	2565
2016 Q1	$1.91M	Buy	+50,000	New	+$1.74M	﹤0.01%	1907
2015 Q4	–	Sell	-50,000	Closed	-$2.04M	–	4064
2015 Q3	$2.04M	Buy	+50,000	New	+$2.19M	﹤0.01%	2084

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

D.E. Shaw & Co's JUNO Position: Q1 2018 in Review

D.E. Shaw & Co sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 288,927 shares — an estimated $13.2M sold.

D.E. Shaw & Co first reported a position in JUNO in Q1 2015 and held it in 10 quarters. The position peaked at $42.9M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

D.E. Shaw & Co reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
D.E. Shaw & Co sold 288,927 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $13.2M.
D.E. Shaw & Co first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 10 quarters.
D.E. Shaw & Co's Juno Therapeutics, Inc. position peaked at $42.9M in Q3 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on D.E. Shaw & Co's 13F filing for Q1 2018, filed 15 May 2018.